Outcomes After Antifungal Discontinuation in Immunocompromised Patients Treated for Histoplasmosis

Clicks: 14
ID: 328425
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #285 of 318 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Histoplasmosis is an important opportunistic infection. Current guidelines recommend prolonged antifungal therapy, typically 12 months of therapy. However, antifungal therapy is occasionally discontinued earlier in clinical practice due to medication intolerance, drug interactions, or adherence challenges. Data describing outcomes after antifungal discontinuation in immunocompromised patients remain limited. Methods We conducted a retrospective cohort study of immunocompromised adults treated for histoplasmosis within a large healthcare system between 2005 and 2025. Patients who discontinued antifungal therapy and had clinical follow-up were included. Patients were categorized according to treatment duration (<12 months vs ≥12 months). The primary outcome was a composite of histoplasmosis-related adverse events after antifungal discontinuation, including relapse, hospitalization attributed to histoplasmosis, or histoplasmosis-related death. Secondary outcomes included all-cause adverse events. Cox proportional hazards models with inverse probability of treatment weighting (IPTW). Results 106 patient met inclusion criteria and 75% presented with disseminated disease. Histoplasmosis-related adverse events were uncommon. Relapse occurred in 7/106 (6.6%), including 3/28 (11%) treated for <12 months and 4/78 (5.1%) treated for ≥12 months. No deaths were attributed to histoplasmosis. Shorter treatment duration was not associated with a higher hazard of histoplasmosis-related outcomes (HR 2.34, 95% CI 0.52–10.62). Lower antigen burden at diagnosis was associated with reduced risk of adverse outcomes. Conclusions Relapse after antifungal discontinuation was uncommon. Baseline disease burden, reflected by antigen levels and timing of diagnosis, appeared to influence post-treatment outcomes. These findings suggest further investigation is warranted into individualized antifungal treatment duration based on disease severity and fungal burden.
Reference Key
openalex_W7212357066 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Caden Tuinstra, Clayton Hicks, Nicolas Barros
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag525
URL
https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofag525/71047448/ofag525.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.